InvestorsObserver
×
News Home

Should You Buy Guardant Health Inc (GH) Stock on Wednesday?

Wednesday, January 18, 2023 02:25 PM | InvestorsObserver Analysts

Mentioned in this article

Should You Buy Guardant Health Inc (GH) Stock on Wednesday?

The market has been high on Guardant Health Inc (GH) stock recently. GH gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Sentiment Score - ,bullish
Guardant Health Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on GH!

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With GH Stock Today?

Guardant Health Inc (GH) stock has risen 3.86% while the S&P 500 is down -1.1% as of 2:12 PM on Wednesday, Jan 18. GH is higher by $1.20 from the previous closing price of $31.12 on volume of 846,832 shares. Over the past year the S&P 500 is lower by -13.77% while GH is down -55.45%. GH lost -$5.94 per share in the over the last 12 months. To screen for more stocks like Guardant Health Inc click here.

More About Guardant Health Inc

Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The company's pipeline includes Guardant Reveal (formerly Lunar-1), for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individuals, with an initial focus on colorectal cancer. Additionally, Guardant offers research development services. The United States accounts for 90% of total revenue, and other markets the remaining 10%. Click Here to get the full Stock Report for Guardant Health Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App